Table 3.
Neurofilament | Cut-Off [pg/mL] | Sensitivity (95% CI) [%] | Specificity (95% CI) [%] | NPV (95% CI) [%] | PPV (95% CI) [%] | ALS vs. | Study |
---|---|---|---|---|---|---|---|
NfL | >2200 | 77 (71–82) | 88 (79–94) | 56 (48–65) | 95 (91–98) | ALS mimics | [105] |
>2200 | - | 85 (79–90) | 75 (69–80) | 87 (81–91) | Other controls | [105] | |
pNfH | >560 | 83 (78–88) | 80 (70–88) | 62 (52–71) | 93 (88–95) | ALS mimics | [105] |
>560 | - | 77 (71–83) | 79 (72–84) | 82 (77–86) | Other controls | [105] | |
NfL | >3819 | 88.4 (78.8–94) | 84.7 (76.8–90.2) | - | - | Disease controls | [100] |
>2453 | 85.4 | 78 | - | - | ALS mimics | [100] | |
pNfH | >618 | 94.2 (86–97.7) | 74.8 (66–81.9) | - | - | Disease controls | [100] |
>768 | 90.7 | 88 | 76 | - | ALS mimics | [100] | |
NfL | 1431 | 79 (66.1–87.6) | 86.4 (75.7–93.6 | - | - | Controls | [103] |
pNFH | 568.5 | 78.7 (67.7–87.3) | 93.3 (85.1–97.8) | - | - | Controls | [103] |